The role of neoadjuvant FLOT chemotherapy with and without omega 3 in locally advanced gastric carcinoma

J BUON. 2020 Nov-Dec;25(6):2672-2677.


Purpose: Gastric is the third leading cause of cancer-related deaths worldwide with two third of the cases presented in advanced stage with resultant increased morbidity and mortality. The purpose of the study was to investigate the nutritional intervention with and without omega 3 fatty acids.

Methods: Forty two cases were randomized into two groups: group; A: FLOT neoadjuvant chemotherapy with omega 3 and group B: FLOT chemotherapy alone in the period from July 2018 to July 2019. We evaluated the radicality of surgical interference, overall response, nutritional status, treatment delivery and toxicity.

Results: The radicality, overall response the SGA score and the bioelectrical impedance parameters were higher in those who received omega 3 with chemotherapy and toxicity was less which was statistically significant.

Conclusions: Omega 3 administrations during chemotherapy in gastric cancer increased the chemotherapy tolerability and decreased the treatment gap between cycles and hence improved gastric cancer resection.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Fatty Acids, Omega-3 / therapeutic use*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoadjuvant Therapy / methods*
  • Stomach Neoplasms / drug therapy*


  • Fatty Acids, Omega-3